Quarterly report pursuant to Section 13 or 15(d)

Commitments and Contingencies (Details Textual)

v3.8.0.1
Commitments and Contingencies (Details Textual) - USD ($)
1 Months Ended 3 Months Ended
Jul. 15, 2011
Dec. 01, 2017
Mar. 31, 2018
Mar. 31, 2017
Dec. 31, 2017
Dec. 31, 2016
Commitments And Contingencies [Line Items]            
Royalty Expense     $ 266,000 $ 186,000    
Accrued Liabilities, Current     5,125,000   $ 4,270,000  
Alliqua Biomedical Subsidiary [Member]            
Commitments And Contingencies [Line Items]            
Contractual Obligation, Due in Next Twelve Months           $ 600,000
Royalty Expense     43 1,900    
Human Longevity, Inc [Member]            
Commitments And Contingencies [Line Items]            
Royalty Expense     266,000 $ 185,000    
Accrued Liabilities, Current     266,000      
Revenue Recognition, Milestone Method, Milestone Expenses     1,000,000      
Human Longevity, Inc [Member] | First Commercial Sale [Member]            
Commitments And Contingencies [Line Items]            
Contractual Obligation, Due in Next Twelve Months     500,000      
Human Longevity, Inc [Member] | Second Commercial Sale [Member]            
Commitments And Contingencies [Line Items]            
Contractual Obligation, Due in Next Twelve Months     $ 500,000      
Cellularity Inc [Member]            
Commitments And Contingencies [Line Items]            
Long-term Purchase Commitment, Amount   $ 842,000        
Noble Fiber Technologies License Agreement [Member]            
Commitments And Contingencies [Line Items]            
Royalty Fee Percentage 9.75%